Pacific Biosciences is trading 11.73% lower at $2.40 as biotech shares weaken and oil prices rise, though no company-specific cause for the October 8 decline was identified. - The latest company news was its TychoBio collaboration, announced October 6. - Oil prices are rising amid reports of explosions in Riyadh; Treasury yields remain near a 24-year high. - These broader pressures may weigh on risk-sensitive stocks but do not establish a company-specific cause.